NBIX
Neurocrine Biosciences, Inc. NASDAQ$135.06
Mkt Cap $13.6B
52w Low $115.66
43.6% of range
52w High $160.18
50d MA $130.36
200d MA $137.33
P/E (TTM)
27.4x
EV/EBITDA
20.7x
P/B
4.0x
Debt/Equity
0.1x
ROE
14.7%
P/FCF
18.8x
RSI (14)
—
ATR (14)
—
Beta
0.35
50d MA
$130.36
200d MA
$137.33
Avg Volume
1.2M
About
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskin…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | AMC | 1.68 | 1.97 | +17.3% | — | — | — | — | — | — | — | — |
| Feb 11, 2026 | AMC | 1.80 | 1.88 | +4.4% | 137.44 | -3.7% | -10.4% | -9.7% | -7.0% | -6.6% | -5.3% | — |
| Oct 28, 2025 | AMC | 1.58 | 2.04 | +29.1% | 147.38 | -5.0% | -6.4% | -6.3% | -2.8% | -3.7% | -2.8% | — |
| Jul 30, 2025 | AMC | 0.98 | 1.06 | +8.2% | 136.76 | +0.2% | -6.2% | -5.7% | -6.4% | -6.1% | -6.1% | — |
| May 5, 2025 | AMC | 0.54 | 0.08 | -85.0% | 109.75 | +12.1% | +8.4% | +10.8% | +7.1% | +5.4% | +9.7% | — |
| Feb 6, 2025 | AMC | 1.62 | 1.00 | -38.3% | 150.51 | -16.3% | -18.5% | -21.1% | -22.4% | -22.1% | -22.4% | — |
| Oct 30, 2024 | AMC | 1.51 | 1.24 | -17.9% | 124.33 | -1.5% | -3.3% | -1.7% | -3.1% | -2.3% | +0.8% | — |
| Aug 1, 2024 | AMC | 1.05 | 0.63 | -40.0% | 153.15 | -0.7% | -0.0% | -3.6% | -4.9% | -5.9% | -4.2% | — |
| May 1, 2024 | AMC | 1.01 | 0.42 | -58.4% | 143.03 | +0.5% | -2.2% | -1.6% | -0.9% | +0.1% | -2.8% | — |
| Feb 7, 2024 | AMC | 1.15 | 1.44 | +25.2% | 136.29 | +0.4% | -1.4% | -2.9% | -4.3% | -1.8% | -3.3% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 22 | Leerink Partners | Maintains | Outperform → Outperform | — | $130.22 | $131.25 | +0.8% | +0.7% | -0.0% | -2.0% | -1.7% | -1.6% |
| Apr 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $131.64 | $132.02 | +0.3% | -2.1% | -4.0% | -0.6% | -0.2% | -2.5% |
| Apr 7 | Canaccord Genuity | Maintains | Buy → Buy | — | $132.48 | $133.35 | +0.7% | -1.2% | +0.5% | -0.6% | -2.7% | -4.6% |
| Apr 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $132.48 | $133.35 | +0.7% | -1.2% | +0.5% | -0.6% | -2.7% | -4.6% |
| Apr 7 | Wedbush | Maintains | Outperform → Outperform | — | $132.48 | $133.35 | +0.7% | -1.2% | +0.5% | -0.6% | -2.7% | -4.6% |
| Apr 7 | Citigroup | Maintains | Buy → Buy | — | $132.48 | $133.35 | +0.7% | -1.2% | +0.5% | -0.6% | -2.7% | -4.6% |
| Apr 6 | Needham | Maintains | Buy → Buy | — | $131.60 | $130.93 | -0.5% | +0.7% | -0.5% | +1.2% | +0.0% | -2.1% |
| Mar 12 | JP Morgan | Maintains | Overweight → Overweight | — | $129.54 | $129.51 | -0.0% | -1.4% | +0.2% | +0.2% | +0.9% | +0.9% |
| Feb 17 | JP Morgan | Maintains | Overweight → Overweight | — | $124.12 | $125.14 | +0.8% | +2.9% | +3.4% | +4.8% | +3.6% | +3.4% |
| Feb 17 | Truist | Maintains | Buy → Buy | — | $124.12 | $125.14 | +0.8% | +2.9% | +3.4% | +4.8% | +3.6% | +3.4% |
Recent Filings
SC TO-T/A
! Medium
Soleno Therapeutics, Inc. -- Tender Offer Amendment
Neurochem Inc. (NBIX) is acquiring Soleno Therapeutics (SLNO) for $53 per share, representing a significant premium to recent trading prices.
Apr 29
SC TO-T
! Medium
Soleno Therapeutics, Inc. -- Tender Offer Amendment
Neurochem Inc. is acquiring Soleno Therapeutics for $53 per share through a tender offer, representing a significant premium for Soleno shareholders.
Apr 28
SC TO-T
!!! Very High
Soleno Therapeutics, Inc. -- Tender Offer
Neurochem Inc. is acquiring Soleno Therapeutics for $53 per share in cash, representing a significant premium for Soleno shareholders.
Apr 20
8-K
Unknown — 8-K Filing
Neurochem/Silence Therapeutics merger is proceeding with no financing risk and a guaranteed 20-day offer period, reducing deal uncertainty and supporting stock prices through closing.
Apr 6
8-K
Unknown — 8-K Filing
Neurocrine (NBIX) is being acquired by an unidentified purchaser in a financing-certain deal, with a tender offer launching within ten business days—providing clarity on deal certainty for shareholders.
Apr 6
8-K
Neurocrine Biosciences Inc -- 8-K Filing
Neurocrine Biosciences reported strong 2025 revenue growth of 22% to $2.83 billion, but guided 2026 INGREZZA sales flat to slightly down at $2.7-2.8 billion, signaling slowing momentum.
Feb 11
Data updated apr 26, 2026 2:20pm
· Source: massive.com